FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225527530> ?p ?o ?g. }

• W4225527530 endingPage "76" @default.
• W4225527530 startingPage "1" @default.
• W4225527530 abstract "Convulsive status epilepticus is defined as ≥ 5 minutes of either continuous seizure activity or repetitive seizures without regaining consciousness. It is regarded as an emergency condition that requires prompt treatment to avoid hospitalisation and to reduce morbidity and mortality. Rapid pre-hospital first-line treatment of convulsive status epilepticus is currently benzodiazepines, administered either by trained caregivers in the community (e.g. buccal midazolam, rectal diazepam) or by trained health professionals via intramuscular or intravenous routes (e.g. midazolam, lorazepam). There is a lack of clarity about the optimal treatment for convulsive status epilepticus in the pre-hospital setting.To assess the current evidence on the clinical effectiveness and cost-effectiveness of treatments for adults with convulsive status epilepticus in the pre-hospital setting.We searched major electronic databases, including MEDLINE, EMBASE, PsycInfo®, CINAHL, CENTRAL, NHS Economic Evaluation Database, Health Technology Assessment Database, Research Papers in Economics, and the ISPOR Scientific Presentations Database, with no restrictions on publication date or language of publication. Final searches were carried out on 21 July 2020.Systematic review of randomised controlled trials assessing adults with convulsive status epilepticus who received treatment before or on arrival at the emergency department. Eligible treatments were any antiepileptic drugs offered as first-line treatments, regardless of their route of administration. Primary outcomes were seizure cessation, seizure recurrence and adverse events. Two reviewers independently screened all citations identified by the search strategy, retrieved full-text articles, extracted data and assessed the risk of bias of the included trials. Results were described narratively.Four trials (1345 randomised participants, of whom 1234 were adults) assessed the intravenous or intramuscular use of benzodiazepines or other antiepileptic drugs for the pre-hospital treatment of convulsive status epilepticus in adults. Three trials at a low risk of bias showed that benzodiazepines were effective in stopping seizures. In particular, intramuscular midazolam was non-inferior to intravenous lorazepam. The addition of levetiracetam to clonazepam did not show clear advantages over clonazepam alone. One trial at a high risk of bias showed that phenobarbital plus optional phenytoin was more effective in terminating seizures than diazepam plus phenytoin. The median time to seizure cessation from drug administration varied from 1.6 minutes to 15 minutes. The proportion of people with recurrence of seizures ranged from 10.4% to 19.1% in two trials reporting this outcome. Across trials, the rates of respiratory depression among participants receiving active treatments were generally low (from 6.4% to 10.6%). The mortality rate ranged from 2% to 7.6% in active treatment groups and from 6.2% to 15.5% in control groups. Only one study based on retrospective observational data met the criteria for economic evaluation; therefore, it was not possible to draw any robust conclusions on cost-effectiveness.The limited number of identified trials and their differences in terms of treatment comparisons and outcomes hindered any meaningful pooling of data. None of the included trials was conducted in the UK and none assessed the use of buccal midazolam or rectal diazepam. The review of economic evaluations was hampered by lack of suitable data.Both intravenous lorazepam and intravenous diazepam administered by paramedics are more effective than a placebo in the treatments of adults with convulsive status epilepticus, and intramuscular midazolam is non-inferior to intravenous lorazepam. Large well-designed clinical trials are needed to establish which benzodiazepines are more effective and preferable in the pre-hospital setting.This study is registered as PROSPERO CRD42020201953.This project was funded by the National Institute for Health Research (NIHR) Evidence Synthesis programme and will be published in full in Health Technology Assessment; Vol. 26, No. 20. See the NIHR Journals Library website for further project information.Epilepsy is a common condition that results from abnormal electrical activity in the brain and causes seizures (stiffening and uncontrolled jerking – known as a ‘fit’). The most severe form of epilepsy is called ‘convulsive status epilepticus’, which involves continuous seizure activity for 5 minutes or more, or repetitive seizures without recovery of consciousness. Convulsive status epilepticus can be very dangerous and requires prompt treatment to avoid hospitalisation and prevent complications. Although several drugs are available for the treatment of convulsive status epilepticus in the community or in the emergency department, it is unclear which one is most effective in stopping seizures. We brought together results from all available clinical studies that looked at the use of drugs to treat adults with convulsive status epilepticus either before arriving at hospital or on arrival at the emergency department. In the literature, we found four studies (1234 adults) assessing drugs delivered by paramedics through an injection into a vein or into muscle. In general, the drugs used by paramedics (benzodiazepines) were effective in stopping seizures, but we were unable to identify any particular drug or way of administering it as being more successful than others. Future research is needed to establish which drugs are most effective and preferable. It is also important to improve adherence to clinical guidelines with regard to the use of these drugs. For the pre-hospital treatment of convulsive status epilepticus, little evidence was available to decide which drug treatment is the best in terms of value for money. Future studies could assess the (1) impact of treatments on costs and outcomes over the whole course of a seizure episode (2) long-term impact of different treatments on patients’ quality of life and (3) health and social care needs." @default.
• W4225527530 created "2022-05-05" @default.
• W4225527530 creator A5013203178 @default.
• W4225527530 creator A5051384943 @default.
• W4225527530 creator A5052750790 @default.
• W4225527530 creator A5066853339 @default.
• W4225527530 creator A5078383863 @default.
• W4225527530 creator A5080292819 @default.
• W4225527530 creator A5083154337 @default.
• W4225527530 creator A5090393467 @default.
• W4225527530 date "2022-03-01" @default.
• W4225527530 modified "2023-09-26" @default.
• W4225527530 title "Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis" @default.
• W4225527530 cites W102573496 @default.
• W4225527530 cites W1146503540 @default.
• W4225527530 cites W1480461509 @default.
• W4225527530 cites W1492947450 @default.
• W4225527530 cites W1559214144 @default.
• W4225527530 cites W173813911 @default.
• W4225527530 cites W1856414226 @default.
• W4225527530 cites W1888779009 @default.
• W4225527530 cites W1896627543 @default.
• W4225527530 cites W1966201948 @default.
• W4225527530 cites W1988978487 @default.
• W4225527530 cites W1989611673 @default.
• W4225527530 cites W2021360813 @default.
• W4225527530 cites W2029569324 @default.
• W4225527530 cites W2036467957 @default.
• W4225527530 cites W2042602590 @default.
• W4225527530 cites W2043834805 @default.
• W4225527530 cites W2047593268 @default.
• W4225527530 cites W2055956675 @default.
• W4225527530 cites W2071725069 @default.
• W4225527530 cites W2073055322 @default.
• W4225527530 cites W2082311304 @default.
• W4225527530 cites W2092013975 @default.
• W4225527530 cites W2094084354 @default.
• W4225527530 cites W2098700447 @default.
• W4225527530 cites W2104104948 @default.
• W4225527530 cites W2111957903 @default.
• W4225527530 cites W2112260196 @default.
• W4225527530 cites W2128919422 @default.
• W4225527530 cites W2130271602 @default.
• W4225527530 cites W2133051471 @default.
• W4225527530 cites W2133838430 @default.
• W4225527530 cites W2134210134 @default.
• W4225527530 cites W2138928595 @default.
• W4225527530 cites W2148248134 @default.
• W4225527530 cites W2151359410 @default.
• W4225527530 cites W2151909850 @default.
• W4225527530 cites W2153928266 @default.
• W4225527530 cites W2160022655 @default.
• W4225527530 cites W2165926195 @default.
• W4225527530 cites W2170047676 @default.
• W4225527530 cites W2184834437 @default.
• W4225527530 cites W2215759330 @default.
• W4225527530 cites W2252496421 @default.
• W4225527530 cites W2343833921 @default.
• W4225527530 cites W2474255262 @default.
• W4225527530 cites W2533784350 @default.
• W4225527530 cites W2592415504 @default.
• W4225527530 cites W2594644573 @default.
• W4225527530 cites W2898310341 @default.
• W4225527530 cites W2970684805 @default.
• W4225527530 cites W2991266411 @default.
• W4225527530 cites W2991792334 @default.
• W4225527530 cites W2998542578 @default.
• W4225527530 cites W3038525021 @default.
• W4225527530 cites W3039119150 @default.
• W4225527530 cites W3140855056 @default.
• W4225527530 cites W4210307844 @default.
• W4225527530 cites W4238760686 @default.
• W4225527530 cites W4250028527 @default.
• W4225527530 cites W4294215472 @default.
• W4225527530 doi "https://doi.org/10.3310/rsvk2062" @default.
• W4225527530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35333156" @default.
• W4225527530 hasPublicationYear "2022" @default.
• W4225527530 type Work @default.
• W4225527530 citedByCount "1" @default.
• W4225527530 countsByYear W42255275302023 @default.
• W4225527530 crossrefType "journal-article" @default.
• W4225527530 hasAuthorship W4225527530A5013203178 @default.
• W4225527530 hasAuthorship W4225527530A5051384943 @default.
• W4225527530 hasAuthorship W4225527530A5052750790 @default.
• W4225527530 hasAuthorship W4225527530A5066853339 @default.
• W4225527530 hasAuthorship W4225527530A5078383863 @default.
• W4225527530 hasAuthorship W4225527530A5080292819 @default.
• W4225527530 hasAuthorship W4225527530A5083154337 @default.
• W4225527530 hasAuthorship W4225527530A5090393467 @default.
• W4225527530 hasBestOaLocation W42255275301 @default.
• W4225527530 hasConcept C118552586 @default.
• W4225527530 hasConcept C126322002 @default.
• W4225527530 hasConcept C168563851 @default.
• W4225527530 hasConcept C17744445 @default.
• W4225527530 hasConcept C194828623 @default.
• W4225527530 hasConcept C197934379 @default.
• W4225527530 hasConcept C199539241 @default.
• W4225527530 hasConcept C27415008 @default.

• next